Tranzyme Pharma’s DIGEST Trial Stopped for Futility After Interim Analysis of the Phase 2b Results

Tranzyme Pharma’s DIGEST Trial Stopped for Futility After Interim Analysis of the Phase 2b Results

[at noodls] – RESEARCH TRIANGLE PARK, N.C., Dec. 17, 2012 (GLOBE NEWSWIRE) — Tranzyme Pharma (Nasdaq:TZYM) today announced it is discontinuing and immediately ending patient enrollment in DIGEST, a Phase 2b trial in … more

View todays social media effects on TZYM

View the latest stocks trending across Twitter. Click to view dashboard

See who Tranzyme is hiring next, click here to view

Share this post